BA
OREX

BlackRock Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

BlackRock Advisors’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$3K Hold
1,808
– – ﹤0.01% 3675
2016
Q3 		$6K Hold
1,808
– – ﹤0.01% 3635
2016
Q2 		$8K Sell
1,808
-2,999
-62% -$13.6K ﹤0.01% 3628
2016
Q1 		$27K Sell
4,807
-10,935
-69% -$142K ﹤0.01% 3367
2015
Q4 		$271K Sell
15,742
-6,651
-30% -$159K ﹤0.01% 2397
2015
Q3 		$472K Sell
22,393
-22,789
-50% -$781K ﹤0.01% 2230
2015
Q2 		$2.24M Buy
45,182
+29,171
+182% +$1.74M ﹤0.01% 1226
2015
Q1 		$1.25M Buy
16,011
+9,445
+144% +$586K ﹤0.01% 1435
2014
Q4 		$398K Sell
6,566
-309
-4% -$15.5K ﹤0.01% 2162
2014
Q3 		$293K Buy
6,875
+123
+2% +$6.61K ﹤0.01% 2367
2014
Q2 		$417K Sell
6,752
-635
-9% -$36.9K ﹤0.01% 2142
2014
Q1 		$480K Buy
7,387
+813
+12% +$55K ﹤0.01% 2070
2013
Q4 		$370K Buy
6,574
+838
+15% +$47.1K ﹤0.01% 2265
2013
Q3 		$352K Buy
5,736
+151
+3% +$10.2K ﹤0.01% 2174
2013
Q2 		$326K Buy
+5,585
New +$344K ﹤0.01% 2149

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock Advisors's OREX Position: Q4 2016 in Review

BlackRock Advisors held its Orexigen Therapeutics, Inc. (OREX) position steady in Q4 2016 at 1,808 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #3675.

BlackRock Advisors first reported a position in OREX in Q2 2013 and has held it in 15 quarters since. The position peaked at $2.24M in Q2 2015. 53 funds tracked by Wall St. Rank hold OREX as of Q4 2016.

  • BlackRock Advisors held 1,808 shares of Orexigen Therapeutics, Inc. worth $3K as of Q4 2016.
  • BlackRock Advisors left its Orexigen Therapeutics, Inc. share count unchanged in Q4 2016.
  • Orexigen Therapeutics, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3675 holding.
  • BlackRock Advisors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Orexigen Therapeutics, Inc. position peaked at $2.24M in Q2 2015.
  • 53 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.